Pharmaceuticals Global News & Press Release Distribution

Pharmaceuticals

All
APAC

GRIT and Quangang Forge Strategic Partnership to Accelerate Localization of Interleukin-2

SHANGHAI, May 31, 2024 /PRNewswire/ -- Shanghai Grit Biotechnology Co., Ltd. (GRIT) and Shandong Quangang Pharmaceutical Co., Ltd. (Quangang) announced the establishment of a formal strategic partnership to leverage both parties' R&D capabilities in innovative T-cell therapy. The objective is to ...

2024-05-31 21:16 2504

Neurophet to participate BIO USA… exploring global partnership and business

* Neurophet's AI brain image analysis technology improves time and cost efficiency for drug development * Aims to create business opportunities with global pharmaceutical companies SEOUL, South Korea, May 31, 2024 /PRNewswire/ -- Neurophet, an artificial intelligence (AI) solution company for...

2024-05-31 21:00 2633

Neurophet to participate BIO USA… exploring global partnership and business

OBiO Technology Officially Launched the Center for Clinical Evaluation and Translation of Advanced Therapies for Pediatric Rare and Genetic Diseases

SHANGHAI, May 30, 2024 /PRNewswire/ -- On May 23, OBiO Technology, a world leading contract development and manufacturing organization for cell and gene therapy, officially launched the "Center for Clinical Evaluation and Translation of Advanced Therapies for Pediatric Rare and Genetic Diseases" ...

2024-05-30 21:00 1958

OBiO Technology Officially Launched the Center for Clinical Evaluation and Translation of Advanced Therapies for Pediatric Rare and Genetic Diseases

Kexing Biopharm Obtained Clinical Trial Approval for its Self-developed Class I Innovative Drug--Long-acting Growth Hormone

SHENZHEN, China, May 30, 2024 /PRNewswire/ -- On the 24th of May, Kexing Biopharm (688136.SH) announced that Shenzhen Kexing Pharmaceutical Co., Ltd., its wholly-owned subsidiary, recently received a Notice of Approval for Drug Clinical Trials from the National Medical Products Administration, ap...

2024-05-30 17:09 1420

Full-Life Technologies Announces Clearance from FDA of IND Application for 225Ac-FL-020 for the Treatment of Metastatic Castration-Resistant Prostate Cancer

HEIDELBERG, Germany , May 29, 2024 /PRNewswire/ -- Full-Life Technologies (Full-Life), a fully integrated global radiotherapeutics company, today announced it has received clearance of its Investigational New Drug (IND) Application from the U.S. Food and Drug Administration (FDA) for clinical tr...

2024-05-30 08:00 1249

AVELOS THERAPEUTICS ANNOUNCES KRW 17 BILLION SERIES B FUNDING ROUND, SURPASSING KRW 30 BILLION TOTAL RAISED

Stassets Investment Leads Round with Major Contribution, Joined by LSK Investment and Shinhan Capital Investment Provides Crucial Resources for Company's Focus on Developing Small Molecule Synthetic New Drugs in Synthetic Lethality, DNA Damage Response, and Cell Cycle Sectors First-In-Class AD1...

2024-05-29 20:00 2277

Shanghai Customs introduces measures to facilitate cross-border trade

SHANGHAI, May 28, 2024 /PRNewswire/ -- A news report from english.shanghai.gov.cn: To better facilitate cross-border trade, Shanghai Customs has introduced 36 measures with a focus on enhancing the experience for businesses. Here are some highlights: 1. Streamlining Customs Procedures: These me...

2024-05-29 11:14 1418

Rege Nephro CO., Ltd. Announces Patient Enrollment for Phase II Clinical Trial of Tamibarotene for ADPKD

KYOTO, Japan, May 28, 2024 /PRNewswire/ -- Rege Nephro CO., Ltd. ( https://www.regenephro.co.jp/en ) has announced that patient enrollment began in April for the second stage of its Phase II clinical trial of tamibarotene as a dev...

2024-05-28 23:00 1900

HanAll Biopharma Signs Licensing Agreement with Turn Biotechnologies to Develop Novel Treatments for Eye and Ear Diseases

* Exclusive agreement allows HanAll to utilize Epigenetic Reprogramming of Aging (ERATM) technology for ophthalmic and otic diseases. * Collaboration aims to leverage HanAll's extensive expertise in ophthalmic and otic diseases and Turn Bio's cellular reprogramming technology to create innova...

2024-05-28 19:00 1469

Neuren Phase 2 trial shows significant improvements in Pitt Hopkins syndrome

Highlights: * Statistically significant improvement from baseline assessed by both clinicians and caregivers in all four efficacy measures specifically designed for Pitt Hopkins syndrome (Wilcoxon signed rank test p<0.05) * Clinician and caregiver global efficacy measures showed a level of i...

2024-05-27 18:00 1915

Lunit to Showcase 7 Studies at ASCO 2024, including AI Innovations in HER2 Quantification, and Multimodal Predictive Models for Immunotherapy Response

- Lunit's ASCO 2024 presentations to highlight advances including HER2 ultra-low detection and AI-powered ICI response prediction models for NSCLC, demonstrating the impact of Lunit SCOPE suite on precision oncology SEOUL, South Korea, May 24, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leadin...

2024-05-24 22:07 5477

Lunit to Showcase 7 Studies at ASCO 2024, including AI Innovations in HER2 Quantification, and Multimodal Predictive Models for Immunotherapy Response

Mabwell Announces 9MW2821 Clinical Data and Latest Progress to be presented at 2024 ASCO Annual Meeting

SHANGHAI, May 24, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company, announced the data and latest progress of the Phase I/II clinical study of 9MW2821, a novel Nectin-4-targeting ADC for multiple advanced solid tumors, which will be reported as an oral pre...

2024-05-24 22:00 5319

Juncell Therapeutics Announces Clinical Data of GC203 TIL therapy in Ovarian Cancer at ASCO 2024

SHANGHAI, May 24, 2024 /PRNewswire/ -- Shanghai Juncell Therapeutics Co., Ltd. (Juncell Therapeutics), a clinical-stage biotech developing innovative Tumor-Infiltrating Lymphocyte (TIL) therapies for cancers, announced latest clinical research results on GC203 (a novel non-viral vector gene-modif...

2024-05-24 20:00 4253

Tyligand Bioscience Announces First Patient Dosed in Phase 1/2 Clinical Trial of TSN1611, a Selective and Orally Bioavailable KRAS G12D Inhibitor

SHANGHAI, May 24, 2024 /PRNewswire/ -- Tyligand Bioscience, a clinical-stage biotechnology company focused on the discovery and development of innovative cancer therapies, announced that the first patient had been dosed in the Phase 1/2 trial of TSN1611 for the treatment of KRAS G12D mutant solid...

2024-05-24 16:33 1803

Dizal Reveals New Findings from Biomarker Analysis, Highlighting Sunvozertinib as an Effective Treatment for Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

* Anittumor efficacy of sunvozertinib was observed in patients regardless of baseline EGFR exon20ins status in plasma ctDNA. * Sunvozertinib could effectively clear EGFR exon20ins in plasma ctDNA, confirming its direct effect on EGFR pathway. * The resistance to sunvozertinib could be thro...

2024-05-24 16:32 1769

ASCO 2024 | Ascentage Pharma Releases Latest Results from Multiple Clinical Studies of Its Lead Drug Candidates

SUZHOU, China and ROCKVILLE, Md., May 23, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that its four abstracts selected for presentations a...

2024-05-24 09:15 1820

Cure Genetics Announced Promising Safety and Efficacy Data of CAR-NKT Product CGC729 for RCC at ASGCT 2024

SUZHOU, China, May 23, 2024 /PRNewswire/ -- On May 10, 2024, Cure Genetics announced the safety and efficacy data of their CAR-NKT product, CGC729, for patients with relapsed and refractory metastatic renal cell carcinoma (R/R mRCC) in an oral presentation at the 27th Annual Meeting of the Americ...

2024-05-23 23:00 2185

Laekna Announces FDA Approval for the Phase III Clinical Trial Protocol of LAE002 (Afuresertib) PLUS LAE001 for the Treatment of Prostate Cancer

SHANGHAI and WARREN, N.J., May 23, 2024 /PRNewswire/ -- Laekna, Inc. (2105.HK), a science-driven, clinical-stage biotechnology company, announced that the company has received approval from the U.S. Food and Drugs Administration for the protocol of the phase III clinical trial of LAE002 (afureser...

2024-05-23 20:42 1824

111, Inc. Announces First Quarter 2024 Unaudited Financial Results

* Turned to Quarterly Operational Profitability for the First Time * Operating Expenses as a Percentage of Revenues Decreased 120 Basis Points YoY to 5.8% * Achieved Positive Operating Cash Flow SHANGHAI, May 23, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading...

2024-05-23 16:43 3463

Nona Biosciences Announces Global License and Option Agreement with AstraZeneca for Monoclonal Antibody to be Developed into Novel Tumor Targeted Therapies

CAMBRIDGE, Mass., May 22, 2024 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing a total solution from "Idea to IND" (I to ITM), ranging from target validation and antibody discovery through preclinical research, announced today that it has entered into a license agreemen...

2024-05-23 07:23 1454

1 ... 14 15 161718 19 20 ... 126

Week's Top Stories

Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies

[Picked up by 284 media titles]

2024-11-20 09:00